9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …

Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …

Introduction EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-
mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are …

Introduction The phase 3 RELAY global study (NCT02411448) revealed significant
improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM+ …

Introduction EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo
(PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for …

Background The EGFR gene encodes a protein that stimulates molecular pathways that
allow the growth and development of the tumor microenvironment. The current preferred …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Background In EGFR mutated, metastatic (met) NSCLC, outcomes from EGFR tyrosine
kinase inhibitors (TKIs) have differed historically by mutation (mut) type present, with lower …